Glioblastoma Pipeline

DelveInsight’s, “Glioblastoma- Pipeline Insight, 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Glioblastoma: Understanding

Glioblastoma: Overview

Glioblastoma (GBM) is an aggressive and highly malignant primary brain tumor that originates from astrocytes, a type of glial cell. It is the most common and deadliest form of glioma, classified as a Grade IV tumor by the World Health Organization (WHO). GBM is characterized by rapid growth, extensive infiltration into surrounding brain tissue, and resistance to conventional therapies. Despite advancements in treatment, prognosis remains poor, with a median survival of approximately 12–18 months after diagnosis.

 

The signs and symptoms of glioblastoma vary depending on the tumor's location and size. Common symptoms include persistent headaches, nausea, vomiting, seizures, and neurological deficits such as weakness, speech difficulties, or vision problems. Cognitive impairment, personality changes, and memory loss can also occur as the tumor affects brain function. Due to its aggressive nature, symptoms often progress rapidly, leading to significant neurological deterioration.

 

Pathophysiologically, glioblastoma arises due to genetic mutations and dysregulation of key signaling pathways that control cell growth and apoptosis. Common mutations involve the epidermal growth factor receptor (EGFR), tumor protein p53 (TP53), and phosphatase and tensin homolog (PTEN) genes. GBM exhibits high cellular heterogeneity, angiogenesis, and infiltration into normal brain tissue, making complete surgical resection nearly impossible. The tumor's microenvironment is also immunosuppressive, limiting the effectiveness of immune-based therapies.

 

Diagnosis of glioblastoma involves neuroimaging and histopathological analysis. Magnetic resonance imaging (MRI) with contrast is the gold standard, revealing an irregularly shaped, ring-enhancing lesion with surrounding edema. A biopsy or surgical resection is required for definitive diagnosis and molecular profiling, which can guide targeted therapy. Advanced techniques like perfusion MRI and positron emission tomography (PET) scans may help assess tumor metabolism and progression.

 

Treatment for glioblastoma is multimodal, combining surgery, radiation, and chemotherapy. Maximal safe resection is performed to reduce tumor burden, followed by radiotherapy and temozolomide (TMZ), an alkylating chemotherapy agent. Tumor-treating fields (TTF) and emerging targeted therapies, such as bevacizumab (anti-VEGF therapy), offer additional options. Despite aggressive treatment, recurrence is common, and new therapeutic strategies, including immunotherapy and gene therapy, are under investigation to improve patient outcomes.

 

"Glioblastoma- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glioblastoma pipeline landscape is provided which includes the disease overview and Glioblastoma treatment guidelines. The assessment part of the report embraces, in depth Glioblastoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Glioblastoma R&D. The therapies under development are focused on novel approaches to treat/improve Glioblastoma. 

 

Glioblastoma Emerging Drugs Chapters

This segment of the Glioblastoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Glioblastoma Emerging Drugs

• BMX-001: BioMimetix 

BMX-001 is a metalloporphyrin, a novel class of redox-active, small molecule. The active center is designed to mimic the center of superoxide dismutase. The primary mechanism of action is modulation of cellular signaling pathways. BMX-001 inhibits both NFkB and HIF-1a. By inhibiting these pro-survival and pro-angiogenic transcription factors, BMX-001 augments tumor killing by radiation therapy and inhibits tumor regrowth. The inhibition of NFkB blocks major components of the inflammatory cascade which simultaneously results in protection of normal tissue from radiation induced injury. BMX-001 is also being developed in head and neck cancer, anal cancer, and rectal cancer. Currently, the drug is in the Phase III stage of its development for the treatment of glioblastoma.

 

• Enzastaurin: Denovo BioPharma

DB102 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that has been studied in more than 3,000 patients across a range of solid and hematological tumor types. DB102 was originally developed by Eli Lilly and for which Denovo has acquired worldwide rights. DB102 received Orphan Drug Designation in DLBCL and glioblastoma multiforme (GBM) from the FDA and EMA and Fast Track Designation from the FDA. DB102 is the world's first oral small-molecule kinase inhibitor targeting PKC. A retrospective analysis found that it has significant curative effects in high-risk DLBCL patients who are DGM1 positive.  The company has initiated a biomarker guided Phase III clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM).

 

• MDNA55: Medicenna Therapeutics, Inc.

MDNA55 is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A.

Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected.

When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2. The drug is currently under Phase II of development.

 

• MN-166: MediciNova

MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses the pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6 and might up-regulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. While considered a New Molecular Entity, or NME, in the United States and Europe, it involves the redirection of an approved drug, ibudilast, which was first approved in Japan more than 20 years ago. Ibudilast has been prescribed to over 3.2 million patients and has a good post-marketing safety profile. Currently, the drug is in Phase II trial for the treatment of Glioblastoma.

 

• TNG456: Tango Therapeutics, Inc.

TNG456 is an experimental targeted therapy developed to address the aggressive nature of glioblastoma, one of the most treatment-resistant brain tumors. Designed to inhibit key molecular pathways involved in tumor proliferation and immune evasion, TNG456 aims to enhance both direct tumor suppression and immune system activation. Preclinical data suggest potential synergy when used alongside standard-of-care therapies like radiotherapy or temozolomide. Its mechanism may involve disrupting tumor metabolism or modulating the tumor microenvironment. TNG456 represents a promising candidate in the evolving landscape of glioblastoma therapeutics, currently under investigation for efficacy and safety. The drug is currently in Phase I/II stage of its development for the treatment of glioblastoma

Further product details are provided in the report……..

 

Glioblastoma: Therapeutic Assessment

This segment of the report provides insights about the different Glioblastoma drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Glioblastoma

There are approx. 190+ key companies which are developing the therapies for Glioblastoma. The companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. Phase III include, BioMimetix.

 

Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Glioblastoma: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glioblastoma therapeutic drugs key players involved in developing key drugs. 

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glioblastoma drugs.

 

Glioblastoma Report Insights

• Glioblastoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Glioblastoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Glioblastoma drugs?
• How many Glioblastoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glioblastoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glioblastoma therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Glioblastoma and their status?
• What are the key designations that have been granted to the emerging drugs?

 

Stay Updated with Us for New Articles:-

• 13 of the most commonly asked questions about Glioblastoma multiforme, Answered
• Niacin fights Glioblastoma, iTeos nets $125M, Pandion reels in $80M, Brii, Chinese partner, FDA to speed up COVID-19 therapies
• DOC1021 – Unveiling Hope: Diakonos Oncology's Breakthrough in Glioblastoma Treatment: AACR 2024
• Safety and preliminary efficacy of AZD1390 + radiation therapy (RT) for glioblastoma (GBM)
• Glioblastoma Multiforme: Advancements in the Treatment Paradigm of the Malignant Condition
• Glioblastoma Multiforme Market: Emerging Pipeline Therapies To Keep A Keen Eye On
• Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma
• Glioma vs. Glioblastoma Therapeutics Space: Unveiling the Battlefront
• Glioblastoma Multiforme Market: Infographics

Also Read:- Latest DelveInsight Blogs